Logo image of RCAT

RED CAT HOLDINGS INC (RCAT) Stock Fundamental Analysis

NASDAQ:RCAT - Nasdaq - US75644T1007 - Common Stock - Currency: USD

7.76  -0.74 (-8.71%)

After market: 7.8199 +0.06 (+0.77%)

Fundamental Rating

3

Taking everything into account, RCAT scores 3 out of 10 in our fundamental rating. RCAT was compared to 124 industry peers in the Electronic Equipment, Instruments & Components industry. RCAT has a bad profitability rating. Also its financial health evaluation is rather negative. RCAT shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year RCAT has reported negative net income.
RCAT had a negative operating cash flow in the past year.
In the past 5 years RCAT always reported negative net income.
RCAT had a negative operating cash flow in each of the past 5 years.
RCAT Yearly Net Income VS EBIT VS OCF VS FCFRCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -74.99%, RCAT is not doing good in the industry: 90.83% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -141.75%, RCAT is doing worse than 89.17% of the companies in the same industry.
Industry RankSector Rank
ROA -74.99%
ROE -141.75%
ROIC N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
RCAT Yearly ROA, ROE, ROICRCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

Looking at the Gross Margin, with a value of 10.92%, RCAT is doing worse than 76.67% of the companies in the same industry.
In the last couple of years the Gross Margin of RCAT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for RCAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5YN/A
RCAT Yearly Profit, Operating, Gross MarginsRCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

3

2. Health

2.1 Basic Checks

RCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RCAT has more shares outstanding
RCAT has more shares outstanding than it did 5 years ago.
RCAT has a better debt/assets ratio than last year.
RCAT Yearly Shares OutstandingRCAT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RCAT Yearly Total Debt VS Total AssetsRCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

RCAT has an Altman-Z score of 12.94. This indicates that RCAT is financially healthy and has little risk of bankruptcy at the moment.
RCAT's Altman-Z score of 12.94 is amongst the best of the industry. RCAT outperforms 90.00% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that RCAT is not too dependend on debt financing.
RCAT has a worse Debt to Equity ratio (0.44) than 65.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z 12.94
ROIC/WACCN/A
WACC9.05%
RCAT Yearly LT Debt VS Equity VS FCFRCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.43 indicates that RCAT should not have too much problems paying its short term obligations.
The Current ratio of RCAT (1.43) is worse than 80.83% of its industry peers.
RCAT has a Quick Ratio of 1.43. This is a bad value and indicates that RCAT is not financially healthy enough and could expect problems in meeting its short term obligations.
RCAT has a worse Quick ratio (0.57) than 92.50% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 0.57
RCAT Yearly Current Assets VS Current LiabilitesRCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

7

3. Growth

3.1 Past

RCAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.62%, which is quite good.
RCAT shows a strong growth in Revenue. In the last year, the Revenue has grown by 49.70%.
Measured over the past years, RCAT shows a very strong growth in Revenue. The Revenue has been growing by 176.68% on average per year.
EPS 1Y (TTM)9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
Revenue 1Y (TTM)49.7%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-60.96%

3.2 Future

The Earnings Per Share is expected to grow by 39.49% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 123.37% on average over the next years. This is a very strong growth
EPS Next Y40.07%
EPS Next 2Y39.61%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue Next Year105.93%
Revenue Next 2Y151.19%
Revenue Next 3Y123.37%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RCAT Yearly Revenue VS EstimatesRCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
RCAT Yearly EPS VS EstimatesRCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCAT. In the last year negative earnings were reported.
Also next year RCAT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCAT Price Earnings VS Forward Price EarningsRCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCAT Per share dataRCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

RCAT's earnings are expected to grow with 39.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.61%
EPS Next 3Y39.49%

0

5. Dividend

5.1 Amount

No dividends for RCAT!.
Industry RankSector Rank
Dividend Yield N/A

RED CAT HOLDINGS INC

NASDAQ:RCAT (2/21/2025, 8:00:01 PM)

After market: 7.8199 +0.06 (+0.77%)

7.76

-0.74 (-8.71%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)12-16 2024-12-16/amc
Earnings (Next)03-17 2025-03-17
Inst Owners32.55%
Inst Owner Change138.21%
Ins Owners18.14%
Ins Owner Change-7.4%
Market Cap622.04M
Analysts85
Price Target15.3 (97.16%)
Short Float %15.64%
Short Ratio0.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-64.08%
Min EPS beat(2)-108.33%
Max EPS beat(2)-19.83%
EPS beat(4)0
Avg EPS beat(4)-87.43%
Min EPS beat(4)-145.1%
Max EPS beat(4)-19.83%
EPS beat(8)1
Avg EPS beat(8)-79.99%
EPS beat(12)2
Avg EPS beat(12)-128.43%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-46.38%
Min Revenue beat(2)-63.55%
Max Revenue beat(2)-29.22%
Revenue beat(4)0
Avg Revenue beat(4)-25.2%
Min Revenue beat(4)-63.55%
Max Revenue beat(4)-1.15%
Revenue beat(8)2
Avg Revenue beat(8)-20.23%
Revenue beat(12)2
Avg Revenue beat(12)-34.16%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)122.22%
EPS NQ rev (1m)-28.57%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-30.56%
EPS NY rev (3m)-56.67%
Revenue NQ rev (1m)-7.24%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 37.77
P/FCF N/A
P/OCF N/A
P/B 23.01
P/tB 996.49
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.21
BVpS0.34
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.99%
ROE -141.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.92%
FCFM N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5YN/A
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.08%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 0.57
Altman-Z 12.94
F-Score3
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)137.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.59%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
EPS Next Y40.07%
EPS Next 2Y39.61%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue 1Y (TTM)49.7%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-60.96%
Revenue Next Year105.93%
Revenue Next 2Y151.19%
Revenue Next 3Y123.37%
Revenue Next 5YN/A
EBIT growth 1Y-5.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.81%
EBIT Next 3Y56.58%
EBIT Next 5YN/A
FCF growth 1Y13.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.2%
OCF growth 3YN/A
OCF growth 5YN/A